PI3K-δ inhibitors have shown impressive activity in lymphoid malignancies but have been hampered by autoimmune and infectious toxicities, leading to market withdrawals. We previously demonstrated activity of the PI3K-δγ inhibitor duvelisib in T cell lymphomas (TCLs) that was associated with inflammatory adverse events. As reported here, we conducted a phase 1b/2a study of duvelisib in combination with either romidepsin (n = 66) or bortezomib (n = 32) in patients with relapsed/refractory TCL and found that the addition of romidepsin, but not bortezomib, appeared to increase efficacy while attenuating PI3K inhibitor-driven toxicity.
View Article and Find Full Text PDFIn preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 chimeric antigen receptor (CAR) T-cell efficacy. We initiated a phase 2 clinical trial of anakinra in patients with relapsed/refractory large B-cell lymphoma and mantle cell lymphoma treated with commercial anti-CD19 CAR T-cell therapy. Here we report a non-prespecified interim analysis reporting the final results from cohort 1 in which patients received subcutaneous anakinra from day 2 until at least day 10 post-CAR T-cell infusion.
View Article and Find Full Text PDFChild maltreatment leads to deleterious effects in virtually every developmental domain, including cognitive, psychological, and behavioral functioning. Although difficulties with coping have been identified as contributing to these effects, less attention has been paid to the precise nature of maltreated children's coping difficulties, particularly in terms of the strategies they use to cope with negative emotions and how these strategies vary with age. We asked maltreated ( = 195) and comparison ( = 103) 10 to 17 year olds to describe emotional experiences and what strategies they used to cope with those emotions.
View Article and Find Full Text PDF